158 related articles for article (PubMed ID: 6373934)
1. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.
Lichtenstein AK; Kahle J; Berek J; Zighelboim J
J Immunol; 1984 Jul; 133(1):519-26. PubMed ID: 6373934
[TBL] [Abstract][Full Text] [Related]
2. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
Lichtenstein AK; Berek J; Kahle J; Zighelboim J
Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
[TBL] [Abstract][Full Text] [Related]
4. Rejection of murine ovarian cancer following treatment with regional immunotherapy: correlations with a neutrophil-mediated activation of cytostatic macrophages.
Lichtenstein A
Cell Immunol; 1985 Sep; 94(2):521-35. PubMed ID: 4028167
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.
Berek JS; Lichtenstein AK; Knox RM; Jung TS; Rose TP; Cantrell JL; Zighelboim J
Cancer Res; 1985 Sep; 45(9):4215-8. PubMed ID: 4028011
[TBL] [Abstract][Full Text] [Related]
6. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model.
Berek JS; Cantrell JL; Lichtenstein AK; Hacker NF; Knox RM; Nieberg RK; Poth T; Elashoff RM; Lagasse LD; Zighelboim J
Cancer Res; 1984 May; 44(5):1871-5. PubMed ID: 6713388
[TBL] [Abstract][Full Text] [Related]
8. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.
Dorigo O; Shawler DL; Royston I; Sobol RE; Berek JS; Fakhrai H
Gynecol Oncol; 1998 Nov; 71(2):204-10. PubMed ID: 9826461
[TBL] [Abstract][Full Text] [Related]
9. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect between neutrophils and Corynebacterium parvum in the process of macrophage activation.
Chapes SK; Haskill S
Cancer Res; 1984 Jan; 44(1):31-4. PubMed ID: 6228293
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of the respiratory burst of murine peritoneal inflammatory neutrophils by conjugation with tumor cells.
Lichtenstein A
Cancer Res; 1987 May; 47(9):2211-7. PubMed ID: 3032419
[TBL] [Abstract][Full Text] [Related]
12. The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumor activity.
Scott MT; Milas L
Cancer Res; 1977 Jun; 37(6):1673-9. PubMed ID: 870181
[TBL] [Abstract][Full Text] [Related]
13. Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells.
Matthews TJ; Weinhold KJ; Langlois AJ; Bolognesi DP
J Natl Cancer Inst; 1985 Oct; 75(4):703-8. PubMed ID: 3862902
[TBL] [Abstract][Full Text] [Related]
14. Nonspecific stimulation of host defense by Corynebacterium kutscheri. I. Antitumor effect.
Kita E; Nishikawa F; Yagyu Y; Hamuro A; Oku D; Emoto M; Katsui N; Tanikawa I; Kashiba S
Nat Immun Cell Growth Regul; 1989; 8(6):313-24. PubMed ID: 2622460
[TBL] [Abstract][Full Text] [Related]
15. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
Vanhaelen CP; Fisher RI
Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
[TBL] [Abstract][Full Text] [Related]
16. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
[TBL] [Abstract][Full Text] [Related]
18. Activity of tumor-associated lymphoid cells at short intervals after administration of irradiated syngeneic and allogeneic tumor cells.
Schick B; Berke G
J Immunol; 1977 Mar; 118(3):986-91. PubMed ID: 321684
[TBL] [Abstract][Full Text] [Related]
19. Protection by polyI:polyC against infection with herpes simplex virus in mice pretreated with Corynebacterium parvum.
Storch E; Baumgartl D; Kirchner H
Nat Immun Cell Growth Regul; 1983-1984; 3(3):134-42. PubMed ID: 6209572
[TBL] [Abstract][Full Text] [Related]
20. Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes.
Lichtenstein A; Berek J
Cancer Immunol Immunother; 1986; 22(1):24-30. PubMed ID: 3708631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
